SCHEMBL6204063

SCHEMBL6204063

CS(=O)(=O)Cc1ccc(C=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.44
ALDH1A1 P00352 7/20 0.42
ALDH1A3 P47895 2/20 0.42
ALDH3A1 P30838 1/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 1/20 0.42
TYR P14679 1/20 0.40
CYP2A13 Q16696 1/20 0.40
STS P08842 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH5A1 P51649 1/20 0.39
ABAT P80404 1/20 0.39
KDM4E B2RXH2 2/20 0.36
HTT P42858 1/20 0.36
RCE1 Q9Y256 1/20 0.36
GRIA4 P48058 1/20 0.36
EPHX2 P34913 1/20 0.36
NR1H4 Q96RI1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772456 0.81 ALDH1A1 (0.46) ALDH1A1LMNAHPGDSMN1; SMN2MAPT
SCHEMBL14919039 0.79 PTGS2 (0.45) CYP2A6ALDH1A1ALDH1A3ALDH3A1LMNA
SCHEMBL2269618 0.78 ALDH5A1 (0.44) CYP2A6ALDH1A1ALDH1A3ALDH3A1LMNA
SCHEMBL15533022 0.78 CA2 (0.56) CYP2A6ALDH1A1ALDH1A3ALDH3A1LMNA
SCHEMBL23905053 0.77 CA2 (0.45) GRIA4
SCHEMBL19838138 0.77 CA2 (0.54) CYP2A6ALDH1A1ALDH1A3ALDH3A1LMNA
SCHEMBL515055 0.75 KMT2A (0.50) CYP2A6ALDH1A1
SCHEMBL514597 0.75 RECQL (0.48) ALDH1A1LMNAMAPTRCE1
SCHEMBL4503685 0.75 CA2 (0.52) CYP2A6ALDH1A1HPGDRCE1
SCHEMBL2937687 0.74 CA2 (0.45) CYP2A6ALDH1A1ALDH1A3ALDH3A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649251-B2 Substituted inhibitors of menin-MLL and methods of use KURA ONCOLOGY, INC. (US) 2023-05-16 US disclosed
EP-1551841-A1 PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS SmithKline Beecham Corporation (US) 2005-07-13 EP disclosed
WO-2004009602-A1 PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-01-29 WO disclosed
WO-2004009602-A1 PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649251-B2 Substituted inhibitors of menin-MLL and methods of use MLLT1, MEN1, MLLT3 CYP2A6 4413/4885ALDH1A1 4538/4885ALDH1A3 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.